EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Total Neoadjuvant Therapy for Rectal Cancer: Which Regimens to Use?

Kentaro Ochiai iD, Neal Bhutiani, Atsushi Ikeda, Abhineet Uppal iD, Michael G White iD, Oliver Peacock, Craig A Messick, Brian K Bednarski, Yi-Qian Nancy You, John M Skibber, George J Chang, Tsuyoshi Konishi iD

Cancers · 31.05.2024 · 16 (11) · 2093

DOI: 10.3390/cancers16112093 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.05.2024. Verfasst von Kentaro Ochiai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colon and Rectal Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Total neoadjuvant therapy (TNT) is a novel strategy for rectal cancer that administers both (chemo)radiotherapy and systemic chemotherapy before surgery. TNT is expected to improve treatment compliance, tumor regression, organ preservation, and oncologic outcomes. Multiple TNT regimens are currently available with various combinations of the treatments including induction or consolidation chemotherapy, triplet or doublet chemotherapy, and long-course chemoradiotherapy or short-course radiotherapy. Evidence on TNT is rapidly evolving with new data on clinical trials, and no definitive consensus has been established on which regimens to use for improving outcomes. Clinicians need to understand the advantages and limitations of the available regimens for multidisciplinary decision making. This article reviews currently available evidence on TNT for rectal cancer. A decision making flow chart is provided for tailor-made use of TNT regimens based on tumor location and local and systemic risk.

Schlagwörter

Stichwörter der Autor:innen

rectal cancertotal neoadjuvant therapywatch and wait

Autor:innen und Institutionen

  • Department of Colon and Rectal Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Colon and Rectal Surgery, The University of Tokyo Hospital, Tokyo 113-8655, Japan.

ORCID-Profile: Kentaro Ochiai, Abhineet Uppal, Michael G White, Tsuyoshi Konishi

Zitieren

APA

Ochiai, K., Bhutiani, N., Ikeda, A., Uppal, A., White, M. G., Peacock, O., Messick, C. A., Bednarski, B. K., You, Y. N., Skibber, J. M., Chang, G. J., & Konishi, T. (2024). Total Neoadjuvant Therapy for Rectal Cancer: Which Regimens to Use?. Cancers, 16(11), 2093. https://doi.org/10.3390/cancers16112093

Vancouver

Ochiai K, Bhutiani N, Ikeda A, Uppal A, White MG, Peacock O, et al. Total Neoadjuvant Therapy for Rectal Cancer: Which Regimens to Use?. Cancers. 2024;16(11):2093. doi:10.3390/cancers16112093

BibTeX
@article{Ochiai2024,
  author = {Ochiai, Kentaro and Bhutiani, Neal and Ikeda, Atsushi and Uppal, Abhineet and White, Michael G and Peacock, Oliver and Messick, Craig A and Bednarski, Brian K and You, Yi-Qian Nancy and Skibber, John M and Chang, George J and Konishi, Tsuyoshi},
  title = {Total Neoadjuvant Therapy for Rectal Cancer: Which Regimens to Use?},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {11},
  pages = {2093},
  doi = {10.3390/cancers16112093}
}
Kostenlos starten →